ENDPOINTS NEWS21h
FDA lifts hold on En­trada's Duchenne drug af­ter two years
Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...
FierceBiotech22h
Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Entrada Therapeutics Inc (TRDA) Receives a Buy from Roth MKM
In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), ...